Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.
Stock data | 2023 | Change |
---|---|---|
Price | $4.57 | N/A |
Market Cap | $1.19B | N/A |
Shares Outstanding | 259.60M | 4.81% |
Employees | 41.00 | N/A |
Shareholder Equity | 69.18M | -25.00% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | -48.09 | N/A |
P/B Ratio | 17.14 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | -0.2418 | N/A |
Earnings | 2023 | Change |
---|---|---|
Earnings | -$16.72M | N/A |
EPS | -0.095 | N/A |
Earnings Yield | -0.0208 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $52.27M | N/A |
Cash on Hand | $44.20M | N/A |
Debt to Equity | 0.0759 | 35.72% |
Current Ratio | $10.17 | -23.34% |